<DOC>
	<DOC>NCT00639483</DOC>
	<brief_summary>To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia</brief_summary>
	<brief_title>Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders [DSM]IVTR criteria and made by a specialist in psychiatry) and acute exacerbation of schizophrenia requiring hospitalization Total PANSS score of ?60 at screening History of schizophrenia of ?10 years (from onset of prodromal symptoms) Exclusion criteria: AxisI DSMIVTR diagnosis other than schizophrenia Less than a full cycle has lapsed at time of screening following the last injection of a depot antipsychotic Currently taking celecoxib or other selective cyclooxygenase 2 inhibitors, or other antiinflammatory medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>